Document Detail


Differential central effects of mineralocorticoid and glucocorticoid agonists and antagonists on blood pressure.
MedLine Citation:
PMID:  2293978     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Systolic blood pressure was measured, using an indirect tail method, in conscious male rats at several time intervals after the intracerebroventricular injection of mineralo-and glucocorticoid agonists and antagonists. Intracerebroventricular administration of the antimineralocorticoid RU 28318 (10 ng) decreased blood pressure, while the antiglucocorticoid RU 38486 (10 ng) caused an increase, which was slower in onset and of longer duration. The effect of the antimineralocorticoid was maximal at 8 h and had disappeared after 24 h. The antiglucocorticoid had a significant effect 24 and 48 h after injection. Neither antagonist was effective when administered sc at the same dose (10 ng). Intracerebroventricular administration of aldosterone (10 ng) and the selective glucocorticoid agonist RU 28362 (10 ng) increased and decreased blood pressure, respectively. Corticosterone given intracerebroventricularly (10-100 ng) did not affect blood pressure unless the dose was increased to 1 microgram. Two weeks after adrenalectomy a decrease in blood pressure was observed when the rats were given 0.9% saline instead of water to drink. Replacement therapy with corticosterone (12.5-mg steroid pellet, sc) restored blood pressure to the level in the sham-operated controls. The chronically elevated level of circulating corticosterone produced by a 100-mg sc corticosterone pellet increased blood pressure. The 12.5-and 100-mg sc corticosterone pellets resulted in plasma corticosterone levels of approximately 3 and 20 micrograms/100 ml, respectively. Intracerebroventricular administration of the glucocorticoid and mineralocorticoid antagonists (10 ng) increased and decreased, respectively, the blood pressure of the adrenalectomized rats receiving corticosterone substitution. From these data we conclude that corticosteroids can affect the central regulation of blood pressure. The mineralo- and glucocorticoids have opposite effects, which differ in onset and duration. The mineralocorticoids increased blood pressure, whereas the glucocorticoid decreased it.
Authors:
D T van den Berg; E R de Kloet; H H van Dijken; W de Jong
Related Documents :
16714158 - Use of aldosterone antagonists in resistant hypertension.
8476368 - Effects of 28-day isolation (esa-isemsi'90) on blood pressure and blood volume regulati...
1267118 - Enflurane anaesthesia for removal of aldosterone producing adenoma.
10338428 - Posttraumatic hypertension secondary to adrenal hemorrhage mimicking pheochromocytoma: ...
5097578 - The dynamics of glomerular ultrafiltration in the rat.
18474178 - Ambulatory blood pressure and cardiovascular risk in chronic kidney disease.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Endocrinology     Volume:  126     ISSN:  0013-7227     ISO Abbreviation:  Endocrinology     Publication Date:  1990 Jan 
Date Detail:
Created Date:  1990-02-07     Completed Date:  1990-02-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375040     Medline TA:  Endocrinology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  118-24     Citation Subset:  AIM; IM    
Affiliation:
Rudolf Magnus Institute for Pharmacology, University of Utrecht, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenalectomy
Aldosterone / pharmacology
Aldosterone Antagonists / pharmacology
Androstanols / pharmacology
Animals
Blood Pressure / drug effects*
Brain / drug effects,  physiology*
Corticosterone / pharmacology
Glucocorticoids / antagonists & inhibitors,  physiology*
Injections, Intraventricular
Male
Mifepristone / pharmacology
Mineralocorticoids / antagonists & inhibitors,  physiology*
Rats
Rats, Inbred Strains
Spironolactone / analogs & derivatives,  pharmacology
Chemical
Reg. No./Substance:
0/Aldosterone Antagonists; 0/Androstanols; 0/Glucocorticoids; 0/Mineralocorticoids; 50-22-6/Corticosterone; 52-01-7/Spironolactone; 52-39-1/Aldosterone; 74915-64-3/11,17-dihydroxy-6-methyl-17-(1-propynyl)androsta-1,4,6-triene-3-one; 76676-34-1/RU 28318; 84371-65-3/Mifepristone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Interactions among the effects of aging, chronic disease, and stress on adrenocortical function in S...
Next Document:  Role of protein kinase C on the steroidogenic effect of angiotensin II in the rat adrenal glomerulos...